Neomycin
As of the edition of 20 October 2026, Neomycin is a drug: marketed, first approved in 1956 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Unknown
- Brand name
- Cortisporin
- First approved
- 1 March 1956 (ES)
- Approvals on record
- 31 in 5 regions
- Holder of the most recent approval
- Cheplapharm Arzneimittel; 18 holders in all
- Withdrawn from market
- 1 January 1982 (in some regions)
- Registered trials
- 26, 1 stopped early
- Disease areas
- Digestive system; Infections; Cancer; Lungs and airways; Immune system; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 8 | 1 | 0 |
| Phase 1 | 6 | 4 | 1 | 0 |
| Phase 2 | 4 | 2 | 1 | 1 |
| Phase 3 | 2 | 0 | 0 | 0 |
| Phase 4 | 3 | 1 | 1 | 0 |
| All trials | 26 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Applicant | 1963 to now |
| AbbVie | Applicant | 1974 to now |
| Cheplapharm Arzneimittel | Later holder | 2000 to now |
| Pfizer | Applicant |